A Study of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Kidney Cancer (AQuOS-RCC).

Trial ID: NCT03108703


Radiation is commonly used to kill cancer cells and shrink tumours. Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues.

SBRT is commonly employed in cancers of the lung, liver, and pancreas, where it is used to shrink tumours that have spread to other parts of the body.

The Trial:

The purpose of this trial is to access the safety and effectiveness of giving five rounds of SBRT to patients with advanced kidney cancer.

Patients on this trial will complete quality of life questionnaires for up to five years after treatment.

Basic Eligibility:

  • Any Subtype
  • Advanced kidney cancer that cannot be removed by surgery
  • Only tumours over 2.5cm in diameter are eligible for SBRT

Additional eligibility criteria will apply. Please speak to your doctor.

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreOdette Cancer Centre Principal InvestigatorDr. William Chu LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreJuravinski Cancer Centre Principal InvestigatorDr. Anand Swaminath LocationHamilton, ON Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!